4-[2-(4-Benzylpiperidin-1-yl)-1-hydroxypropyl]phenol;hydrochloride | 23210-57-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[2-(4-Benzylpiperidin-1-yl)-1-hydroxypropyl]phenol;hydrochloride
• 英文别名: 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol;hydrochloride
• CAS: 23210-57-3
• 化学式: C21H28ClNO2
• 分子量: 361.9
• InChiKey: IJGUUFKAECMEDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.19
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  43.7
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
  申请人：Lachesis Biosciences Limited

  公开号：US10471040B2

  公开（公告）日：2019-11-12

  The present invention relates generally to intranasal pharmaceutical compositions. In particular, the present invention is directed to sustained, enhanced delivery of pharmaceutical agents across the nasal mucosa for systemic drug delivery.

  本发明一般涉及鼻内药物组合物。特别是，本发明涉及通过鼻粘膜持续、增强地输送药剂，以达到全身给药的目的。
• EP3200828A1
  申请人：——

  公开号：EP3200828A1

  公开（公告）日：2017-08-09
• INTRANASAL COMPOSITIONS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISEASES AND DISORDERS
  申请人：Lachesis Biosciences Limited

  公开号：EP3200828B1

  公开（公告）日：2020-08-12
• Intranasal Compositions For Treatment of Neurological And Neurodegenerative Diseases And Disorders
  申请人：Lachesis Biosciences Limited

  公开号：US20170239209A1

  公开（公告）日：2017-08-24

  The present invention relates generally to intranasal pharmaceutical compositions. In particular, the present invention is directed to sustained, enhanced delivery of pharmaceutical agents across the nasal mucosa for systemic drug delivery.
• [EN] INTRANASAL COMPOSITIONS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISEASES AND DISORDERS<br/>[FR] COMPOSITIONS INTRANASALES POUR LE TRAITEMENT DE MALADIES ET TROUBLES NEUROLOGIQUES OU NEURODÉGÉNÉRATIFS
  申请人：LACHESIS BIOSCIENCES PTY LTD

  公开号：WO2016049700A1

  公开（公告）日：2016-04-07

  The present invention relates generally to intranasal pharmaceutical compositions. In particular, the present invention is directed to sustained, enhanced delivery of pharmaceutical agents across the nasal mucosa for systemic drug delivery.